|
|
PACE Asia-Europe Expert Dialogue Diabetes and Vascular Protection Macrovascular Disease in Diabetes Opportunities for Management
|
|
|
|
Diabetes and Cardiovascular Disease: Time To Act!
|
|
|
|
Framingham Study: CVD Events in Diabetic Patients (35–64yrs) 30-Year Follow-Up
|
|
|
|
Survival Post-MI in Diabetic and Non-diabetic Men and Women
|
|
|
|
TemporalMortalityTrendsPatientswithandwithoutDiabetesSufferingaMyocardialInfarction(acomparisonof1762patientsin1995with1642patientsin2003)
|
|
|
|
Characteristics of LDL Subclasses
|
|
|
|
The Absolute Concentration of LDL-C Can be Misleading in Subjects with Small, Dense LDL?
|
|
|
|
LDL Subfractions “Control” vs Patient with Insulin Resistance
|
|
|
|
EffectsofStatins
|
|
|
|
Statins:The Evidence Base.
|
|
|
|
Major Coronary Events in 4S: with and Without Diabetes
|
|
|
|
CHD Prevention Trials with Statins in Diabetic Patients Subgroup Analyses.
|
|
|
|
Heart Protection Study Diabetes Subgroups With/Without CHD or Other CVD
|
|
|
|
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease Treat to New Targets Trial (TNT)
|
|
|
|
Changes in LDL Cholesterol
|
|
|
|
Time to First Major Cardiovascular Event Patients With Diabetes TNT Study
|
|
|
|
Acute Coronary Syndromes and Diabetes. Is Intensive Lipid Lowering Therapy Beneficial? Results of the PROVE IT-TIMI 22 Trial
|
|
|
|
High-Dose Atorvastatin after Stroke or Transient Ischaemic Attack The SPARCL Trial
|
|
|
|
Implications of Recent Trials Adult Treatment Panel III Guidelines Diabetes
|
|
|
|
CARDS: Collaborative AtoRvastatin Diabetes Study
|
|
|
|
Median Lipid Levels by Treatment
|
|
|
|
Cumulative Hazard for Primary Endpoint
|
|
|
|
Treatment effect on Primary Endpoint
|
|
|
|
Effect of Atorvastatin on Major CVD Events Patients with Diabetes and Metabolic Syndrome
|
|
|
|
Cumulative Hazard for Stroke
|
|
|
|
Predictors of Stroke after Multivariate Analysis
|
|
|
|
Cumulative Hazard for Primary Endpoint in Older People
|
|
|
|
CARDS: Safety Overview
|
|
|
|
CARDS: Safety Overview
|
|
|
|
CARDS: Safety Overview Muscle-related Adverse Events
|
|
|
|
CARDS: Safety Overview Muscle-related Adverse Events
|
|
Share this page with your colleagues and friends: